Bevacizumab increases the risk of arterial ischemia: A large study in cancer patients with a focus on different subgroup outcomes

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1404-1412

  Schutz, F A B ^a   Je, Y ^b   Azzi, G R ^a   Nguyen, P L ^a   Choueiri, T K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Arterial thromboembolic events; Bevacizumab; Ischemia; Meta analysis; Monoclonal antibody; Myocardial infarction

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERFERON; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM ISCHEMIA; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; COLORECTAL CARCINOMA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIA; KIDNEY CANCER; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MESOTHELIOMA; META ANALYSIS; PANCREAS CANCER; PERIPHERAL ARTERIAL ISCHEMIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SUPERIOR MESENTERIC THROMBOSIS; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79957790694     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq587     Document Type: Article

References (42)

1. Genentech. AVASTIN prescribing information. http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf (6 January 2010, date last accessed).
2. National Cancer Institute, US National Institutes of Health. http://www.cancer.gov/clinicaltrials/search (6 January 2009, date last accessed).
3. Abou-Jawde R, Choueiri T, Alemany C, Mekhail T. An overview of targeted treatments in cancer. Clin Ther 2003; 25(8): 2121-2137.
4. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99(16): 1232-1239.
5. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49(3): 287-297.
6. Hopewell S, Clarke M, Moher D, et al. CONSORT for reporting randomised trials in journal and conference abstracts. Lancet 2008; 371(9609): 281-283.
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-188.
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-560.
9. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50(4): 1088-1101.
10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-634.
11. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370(9605): 2103-2111.
12. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27(20): 3385-3390.
13. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27(8): 1227-1234.
14. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26(33): 5422-5428.
15. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12): 2013-2019.
16. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25(12): 1539-1544.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342.
18. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666-2676.
19. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23(4): 792-799.
20. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27(13): 2231-2237.
21. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21(1): 60-65.
22. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23(16): 3697-3705.
23. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25(30): 4743-4750.
24. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-smallcell lung cancer. J Clin Oncol 2004; 22(11): 2184-2191.
25. Moehler M, Sprinzl MF, Abdelfattah M, et al. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15(4): 449-456.
26. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355(24): 2542-2550.
27. Price T, Gebski V, van Hazel G, et al. International multi-centre randomised Phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): final safety analysis of the AGITG MAX trial. Proc Am Soc Clin Oncol 2008; 26 (15 Suppl): 4029.
28. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as firstline therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc Am Soc Clin Oncol 2008; 26 (15 Suppl): abs LBA1011.
29. Kindler H, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). Proc Am Soc Clin Oncol 2007; 25 (18 Suppl): 4508.
30. Karrison T, Kindler H, Gandara D, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/ cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). Proc Am Soc Clin Oncol 2007; 25 (18 Suppl): 7526.
31. Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf 2008; 7(6): 703-716.
32. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8(2): 191-202.
33. Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000; 18(10): 2169-2178.
34. Jafri M, Protheroe A. Cisplatin-associated thrombosis. Anticancer Drugs 2008; 19(9): 927-929.
35. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 99(3): 557-561.
36. Choueiri TK, Atkins MB. Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit? Nat Rev Clin Oncol 2009; 6(12): 679-680.
37. Streiff MB. Diagnosis and initial treatment of venous thromboembolism in patients with cancer. J Clin Oncol 2009; 27(29): 4889-4894.
38. Stone JR, Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium 2002; 9(4): 231-238.
39. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49(3): 568-581.
40. Gonzalez-Pacheco FR, Deudero JJ, Castellanos MC, et al. Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am J Physiol Heart Circ Physiol 2006; 291(3): H1395-H1401.
41. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96(12): 1788-1795.
42. Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009; 7(1): 171-181.